Syndax Pharmaceuticals, Inc. (SNDX) is a publicly traded Healthcare sector company. As of May 21, 2026, SNDX trades at $20.23 with a market cap of $1.72B and a P/E ratio of -6.10. SNDX moved +4.08% today. Year to date, SNDX is -0.45%; over the trailing twelve months it is +90.44%. Its 52-week range spans $8.58 to $25.59. Analyst consensus is strong buy with an average price target of $39.91. Rallies surfaces SNDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What do analysts rate SNDX?
12 analysts cover SNDX: 0 strong buy, 12 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $39.91.
Metzger Michael A sold 17.16K (~$360.82K) on Feb 9, 2026.
Goldan Keith A. sold 3.41K (~$71.71K) on Feb 9, 2026.
Metzger Michael A sold 7.41K (~$152.84K) on Feb 6, 2026.
Common questions about SNDX
What do analysts rate SNDX?
12 analysts cover SNDX: 0 strong buy, 12 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $39.91.
Does Rallies show SNDX price targets?
Yes. Rallies tracks SNDX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is SNDX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SNDX. It does not provide personalized investment advice.
